☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.42

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

---

---

•	Net revenue increased 11.9% to $387.4 million

•	Comparable store sales growth of 7.0%; Adjusted comparable store sales growth of 6.8%

•	67th consecutive quarter of positive comparable store sales growth

•	Net income of $5.8 million; Adjusted net income increased 57.7% to $9.2 million

•	Adjusted EBITDA increased 7.3% to $38.8 million

•	Diluted EPS of $0.07; Adjusted diluted EPS increased 15.7% to $0.12

•

Net revenue increased 11.9% to $387.4 million from $346.1 million for the third quarter of 2017. The Company expanded its contact lens distribution relationship with Walmart during the quarter, which added approximately $3 million to net revenues or approximately 90 basis points to net revenue growth. Net revenue growth was negatively impacted by approximately 40 basis points by the timing of unearned revenue.

•	Comparable store sales growth of 7.0% and adjusted comparable store sales growth of 6.8% were primarily driven by increases in customer transactions.

•	The Company opened 18 new stores, closed one store and ended the quarter with 1,067 stores. Overall, store count grew 7.1% from September 30, 2017 to September 29, 2018.

•

As a result of changes in California law, in the fourth quarter of 2017, FirstSight Vision Services, Inc. (“FirstSight”), the Company's HMO subsidiary, ceased the sale of vision care products in Walmart locations that were not operated by the Company, reducing its net revenue and associated costs by approximately $1.8 million in the third quarter of 2018, with an immaterial impact on income from operations.

•

Costs applicable to revenue increased 12.5% to $182.6 million from $162.4 million for the third quarter of 2017. As a percentage of net revenue, costs applicable to revenue increased 20 basis points to 47.1% from 46.9% for the third quarter of 2017. This increase as a percentage of net revenue was primarily driven by higher optometrist costs and the recently expanded contact lens distribution relationship with Walmart, partially offset by a higher mix of eye exam sales as a result of the Company's growing managed care business and vendor rebates.

•

Selling, general and administrative expenses (“SG&A”) increased 21.9% to $184.4 million from $151.3 million for the third quarter of 2017. As a percentage of net revenue, SG&A increased 390 basis points to 47.6% from 43.7% for the third quarter of 2017. This increase as a percentage of net revenue was primarily driven by stock compensation expense, cash expenses pursuant to an incentive plan for non-executive employees, investment in advertising, and incremental corporate expense as a result of becoming a public company, partially offset by the expense leverage resulting from the recently expanded contact lens distribution relationship with Walmart.

---

•	Depreciation and amortization expense increased 24.3% to $19.1 million from $15.4 million for the third quarter of 2017, primarily driven by new store openings, as well as investments in optical laboratories, distribution centers and information technology infrastructure, including omni-channel platform related investments.

•	Interest expense, net, decreased $5.4 million compared to the third quarter of 2017, primarily driven by a $4.5 million decrease resulting from the payoff of the $125.0 million in second lien term loans and $235.0 million in outstanding amount of first lien term loans during the fourth quarter of 2017.

•	Income tax benefit of $16.4 million compared to income tax provision of $0.2 million for the third quarter of 2017, due to an income tax benefit associated with current period pre-tax losses at the Company's statutory federal and state rate, and a $13.9 million income tax benefit resulting primarily from stock option exercises.

•	Net income was $5.8 million compared to net income of $1.5 million for the third quarter of 2017. Net margin increased 110 basis points to 1.5% from 0.4% for the third quarter of 2017. Diluted EPS was $0.07 compared to $0.03 per share for the third quarter of 2017.

•	Adjusted net income increased 57.7% to $9.2 million compared to $5.8 million for the third quarter of 2017. Adjusted diluted EPS increased 15.7% to $0.12 per diluted share compared to $0.10 per diluted share for the third quarter of 2017.

•

Adjusted EBITDA increased 7.3% to $38.8 million compared to $36.2 million for the third quarter of 2017. Adjusted EBITDA growth was negatively impacted 280 basis points from the net change in margin on unearned revenue. Adjusted EBITDA margin decreased to 10.0% from 10.4% for the third quarter of 2017, primarily due to higher optometrist costs, investment in advertising, public company expenses and the net change in margin on unearned revenue.

•	Net revenue increased 12.1% to $1.2 billion from $1.1 billion for the same period of 2017.

•	Comparable store sales growth of 7.4% and adjusted comparable store sales growth of 6.6% were primarily driven by increases in customer transactions and, to a lesser extent, average ticket.

•	The Company opened 58 new stores, closed four stores and ended the period with 1,067 stores. Overall, store count grew 7.1% from September 30, 2017 to September 29, 2018.

•

As a result of changes in California law, in the third quarter of 2017, the Legacy segment began providing eye examination services that previously had been provided by FirstSight, increasing Legacy comparable store sales growth by 135 basis points. Also, in the fourth quarter of 2017, FirstSight ceased the sale of vision care products in Walmart locations that are not operated by the Company, reducing its net revenue and associated costs by approximately $5.4 million for the nine months ended September 29, 2018, with an immaterial impact on income from operations.

•

Costs applicable to revenue increased 11.5% to $540.1 million from $484.6 million for the same period of 2017. As a percentage of net revenue, costs applicable to revenue decreased 30 basis points to 45.7% from 46.0% for the same period of 2017. This decrease as a percentage of net revenue was primarily driven by a higher mix of exam sales as a result of the Company's growing managed care business, higher vendor rebates and a $2.3 million inventory write-off in the same period of 2017, partially offset by higher optometrist costs and the recently expanded contact lens distribution relationship with Walmart.

•

SG&A increased 16.6% to $519.6 million from $445.7 million for the same period of 2017. As a percentage of net revenue, SG&A increased 170 basis points to 44.0% from 42.3% for the same period of 2017. This increase as a percentage of net revenue was primarily driven by stock compensation expense, cash expenses pursuant to a long-term incentive plan for non-executive employees, advertising and incremental corporate expenses as a result of becoming a public company.

•	Depreciation and amortization expense increased 21.8% to $54.1 million from $44.4 million for the same period of 2017, primarily driven by new store openings, as well as investments in optical laboratories, distribution centers and information technology infrastructure, including omni-channel platform related investments.

•	Interest expense, net, decreased $12.8 million compared to the same period of 2017, primarily driven by a $13.4 million decrease resulting from the payoff of the $125.0 million in second lien term loans and $235.0 million in outstanding amount of first lien term loans during the fourth quarter of fiscal year 2017.

•	Income tax benefit of $7.9 million compared to income tax provision of $9.3 million for the same period of 2017, due to an income tax provision on current year pre-tax net income at the Company's statutory federal and state rate, and an $18.0 million income tax benefit resulting from stock option exercises.

•	Net income was $43.9 million compared to $17.1 million for the same period of 2017. Net margin increased 210 basis points to 3.7% from 1.6% for the same period of 2017. Diluted EPS was $0.56 compared to $0.29 for the same period of 2017.

•	Adjusted net income increased 44.8% to $52.2 million compared to $36.1 million for the same period of 2017. Adjusted diluted EPS increased 7.4% to $0.66 per diluted share compared to $0.62 per diluted share for the same period of 2017.

•	Adjusted EBITDA increased 8.9% to $146.7 million compared to $134.7 million for the same period of 2017. Adjusted EBITDA margin declined to 12.4% from 12.8% for the same period of 2017, primarily due to higher optometrist costs, investment in advertising, and public company expenses.

---

•	The Company’s cash balance was $48.9 million as of September 29, 2018. The Company had no borrowings under its $100 million first lien revolving credit facility, exclusive of letters of credit of $5.5 million.

•	Total debt was $574.8 million as of September 29, 2018, consisting of outstanding first lien term loans and capital lease obligations.

•	Cash flows from operating activities for the first nine months of 2018 were $116.0 million compared to $96.3 million for the same period of 2017.

•	Capital expenditures for the first nine months of 2018 totaled $78.8 million compared to $67.1 million for the same period of 2017.

•	On October 9, 2018, the Company amended its credit agreement to establish new first lien term loans in an aggregate principal amount of $200.0 million (“Term A Loans”) to prepay a portion of the first lien term loans outstanding. The initial applicable interest rate margin is 1.75% for new first lien LIBOR Loans and 0.75% for new first lien ABR loans.

•

On November 12, 2018, the Company entered into a new letter agreement with Essilor of America, Inc. (“Essilor”), which, when effective, will replace the current letter agreement, dated May 25, 2011, between the Company and Essilor. The new agreement extends the term of the Company’s contractual arrangement with Essilor from June 1, 2019 until May 31, 2023, unless terminated earlier or extended pursuant to its terms. Under the agreement, Essilor has the sole and exclusive right to supply certain lenses for eyeglasses to the Company.

•	The Company expects adjusted same store sales growth to be at or above the top end of the range in the previously provided 2018 Outlook.

•

In addition, the Company's AC Lens business is generating higher net revenue, including the Walmart expanded contact lens distribution relationship that is estimated to add at least $10 million to 2018 net revenue. As a result, the Company expects net revenue to be above the range in the previously provided 2018 Outlook. The expanded Walmart relationship is expected to provide minimal contribution to profitability and no impact to adjusted same store sales growth.

•

The Company expects to incur approximately $4 to $5 million relating to certain growth investments and incremental operating expenses by the end of 2018 that were not contemplated in the original 2018 Outlook. These items include investments to support the Company's managed care growth and support for a citizens' initiative in Oklahoma, as well as higher public company expenses. As a result, the Company expects Adjusted EBITDA and Adjusted Net Income for fiscal 2018 to be in the lower half of the range in the previously provided 2018 Outlook.

•	The Company expects capital expenditures to be near the high end of the range in the previously provided 2018 Outlook, driven by growth investments.

---

---

---

---

---

---

---

---

(a)	Non-cash charges related to stock-based compensation programs, which vary from period to period depending on the timing of awards.

(b)	Fees associated with the borrowing of $175.0 million in additional principal under our first lien credit agreement during the first fiscal quarter of 2017.

(c)	Reflects write-off of capitalized software and property and equipment for the three and nine months ended September 29, 2018. Reflects the complete write-off of a cost basis investment for the nine months ended September 30, 2017.

(d)	Reflects write-offs of inventory relating to the expiration of a specific type of contact lenses that could not be sold and required disposal.

(e)	Reflects management fees paid to KKR Sponsor and Berkshire in accordance with our monitoring agreement with them. The monitoring agreement was terminated automatically in accordance with its terms upon the consummation of the IPO in October 2017

(f)

Pre-opening expenses, which include marketing and advertising, labor and occupancy expenses incurred prior to opening a new store, are generally higher than comparable expenses incurred once such store is open and generating revenue. We believe that such higher pre-opening expenses are specific in nature and amount to opening a new store and as such, are not indicative of ongoing core operating performance. We adjust for these costs to facilitate comparisons of store operating performance from period to period. Pre-opening costs are permitted exclusions in our calculation of Adjusted EBITDA pursuant to the terms of our first lien credit agreement.

(g)	Consists of the non-cash portion of rent expense, which reflects the extent to which our straight-line rent expense recognized under GAAP exceeds or is less than our cash rent payments.

(h)	Amounts accrued related to settlement of litigation.

(i)	Expenses related to our secondary public offerings for the three and nine months ended September 29, 2018.

(j)

Cash expenses pursuant to a long-term incentive plan for non-executive employees who were not participants in the management equity plan for the three and nine months ended September 29, 2018.  This plan was effective in 2014 following the acquisition of the Company by KKR, and this payout was triggered as a result of the secondary offering of common stock by KKR and other selling shareholders completed in the third quarter of 2018.

(k)

Other adjustments include amounts that management believes are not representative of our operating performance, including our share of losses on equity method investments of $0.4 million and $0.4 million for the three months ended September 29, 2018 and September 30, 2017 and $1.0 million and $0.7 million for the nine months ended September 29, 2018 and September 30, 2017, respectively; the amortization impact of the KKR Acquisition-related adjustments (e.g., fair value of leasehold interests) of $0.2 million and $(0.1) million for the three months ended September 29, 2018 and September 30, 2017 and $0.3 million, and $(0.2) million for the nine months ended September 29, 2018 and September 30, 2017, respectively; expenses related to preparation for being an SEC registrant that were not directly attributable to the IPO and therefore not charged to equity of $0.6 million and $1.8 million for the three and nine months ended September 30, 2017, respectively; differences between the timing of expense versus cash payments related to contributions to charitable organizations of $(0.3) million for each of the three months ended September 29, 2018 and September 30, 2017 and $(0.8) million for each of the nine months ended September 29, 2018 and September 30, 2017, respectively; costs of severance and relocation of $0.3 million and $0.7 million for the three months ended September 29, 2018 and September 30, 2017 and, $0.9 million and $1.0 million for the nine months ended September 29, 2018 and September 30, 2017 respectively; excess payroll taxes related to stock option exercises of $0.9 million and $1.2 million for the three and nine months ended September 29, 2018, respectively; and other expenses and adjustments totaling $0.4 million for the three months ended September 29, 2018 and September 30, 2017 and $0.5 million for the nine months ended September 29, 2018 and September 30, 2017, respectively.

---

(l)

Amortization of acquisition intangibles related to the increase in the carrying values of intangible assets as a result of the KKR Acquisition of $1.9 million for each of the three months ended September 29, 2018 and September 30, 2017 and $5.6 million for each of the nine months ended September 29, 2018 and September 30, 2017. Amortization of deferred financing costs is primarily associated with the March 2014 term loan borrowings in connection with the KKR Acquisition and, to a lesser extent, amortization of deferred loan discount costs associated with the May 2015 and February 2017 incremental first lien term loans and the November 2017 first lien term loan refinancing, aggregating to $0.4 million, $1.0 million, $1.3 million and $3.1 million for the three months ended September 29, 2018 and September 30, 2017 and nine months ended September 29, 2018 and September 30, 2017, respectively.

(m)	Tax benefit associated with accounting guidance adopted at the beginning of fiscal year 2017 (Accounting Standards Update 2016-09, Compensation - Stock Compensation), requiring excess tax benefits to be recorded in earnings as discrete items in the reporting period in which they occur.

(n)	Represents the tax effect of the total adjustments at our combined statutory federal and state income tax rates.

(a)

Total comparable store sales calculated based on consolidated net revenue excluding the impact of (i) corporate/other segment net revenue, (ii) sales from stores opened less than 12 months, (iii) stores closed in the periods presented, (iv) sales from partial months of operation when stores do not open or close on the first day of the month, and (v) if applicable, the impact of a 53rd week in a fiscal year. Comparable store sales growth for America's Best, Eyeglass World, Military, and Fred Meyer is calculated based on cash basis revenues consistent with what the Chief Operating Decision Maker reviews, and consistent with reportable segment revenues presented in the "Segment Reporting" footnote in our condensed consolidated financial statements included in Part I. Item 1. of our quarterly report on Form 10-Q, with the exception of the legacy segment, which is adjusted as noted in (b) (ii) below.

(b)

There are two differences between total comparable store sales growth based on consolidated net revenue and adjusted comparable store sales growth: (i) adjusted comparable store sales growth includes the effect of deferred and unearned revenue as if such revenues were earned at the point of sale, resulting in a decrease of 0.1% and 1.3% from total comparable store sales growth based consolidated net revenue for the three months ended September 29, 2018 and September 30, 2017, respectively, and a decrease of 0.7% and 0.5% from total comparable store sales growth based on consolidated net revenue for the nine months ended September 29, 2018 and September 30, 2017, respectively, and (ii) adjusted comparable store sales growth includes retail sales to the legacy partner’s customers (rather than the revenues recognized consistent with the management & services agreement), resulting in a decrease of 0.1% from total comparable store sales growth based on consolidated net revenue for the three months ended September 29, 2018, and a decrease of 0.1% and 0.2% from total comparable store sales growth based on consolidated net revenue for the nine months ended September 29, 2018 and September 30, 2017, respectively.

---